Business

Lantheus Holdings Announces Senior Leadership Appointment

Company Appoints Paul Blanchfield as Chief Commercial Officer NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”),

articleLantheus Holdings, Inc.January 27, 20204/company/lantheus-holdings-inc/news/lantheus-holdings-announces-senior-leadership-appointment
Lantheus Holdings Announces Senior Leadership Appointment

About this update from Lantheus Holdings, Inc.

[{"type":"text","content":"\nCompany Appoints Paul Blanchfield as Chief Commercial Officer\n\n NORTH BILLERICA, Mass.--(BUSINESS WIRE)--\nLantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced the appointment of Paul Blanchfield as Chief Commercial Officer, effective January 27, 2020. In his role, Mr. Blanchfield will report directly to Lantheus President and Chief Executive Officer, Mary Anne Heino.\n\n\n“With his extensive operational experience and deep expertise in commercializing rare disease products, Paul will be a valuable addition to our executive leadership team as we execute our long-term growth strategy,” said Mary Anne Heino, President and Chief Executive Officer of Lantheus. “Following the recent appointment of Dr. Istvan Molnar as Chief Medical Officer, the addition of Paul to our team further enhances our exceptional expertise in complex manufacturing, supply chain and commercial excellence. We look forward to working with Paul and the rest of our team as we continue the exciting momentum we have generated as we focus on building sustainable, long-term shareholder value.”\n\n\nMr. Blanchfield joins Lantheus from Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion dollar P&L covering multiple rare diseases products. Prior to his time at Takeda, Mr. Blanchfield served in several different roles at Shire Plc across almost 6 years, including as the Head of U.S. Immunology, General Manager of Nordic-Baltics, Head of Corporate Strategy, and Chief of Staff to the CEO. In his time at Shire, Mr. Blanchfield launched multiple products, worked across nine different countries, oversaw a restructuring to increase commercial focus and reduce costs, and led efforts in M&A, corporate defense, integration, and long-term corporate and portfolio strategy. Prior to his time at Shire, Mr. Blanchfield worked at McKinsey & Company for 5 years, where he focused on health care, marketing, and sales. Mr. Blanchfield earned an MBA / MA in Education from Stanford University and an AB in Economics from Duke University.\n\n\nAbout Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.\n\n\nLantheus Holdings, Inc. ...

More updates from Lantheus Holdings, Inc.